225 related articles for article (PubMed ID: 32776290)
1. Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
Heeke AL; Xiu J; Elliott A; Korn WM; Lynce F; Pohlmann PR; Isaacs C; Swain SM; Vidal G; Schwartzberg LS; Tan AR
Breast Cancer Res Treat; 2020 Nov; 184(2):265-275. PubMed ID: 32776290
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types.
Heeke AL; Pishvaian MJ; Lynce F; Xiu J; Brody JR; Chen WJ; Baker TM; Marshall JL; Isaacs C
JCO Precis Oncol; 2018; 2018():. PubMed ID: 30234181
[TBL] [Abstract][Full Text] [Related]
3. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
4. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers.
Domagala P; Jakubowska A; Jaworska-Bieniek K; Kaczmarek K; Durda K; Kurlapska A; Cybulski C; Lubinski J
PLoS One; 2015; 10(6):e0130393. PubMed ID: 26083025
[TBL] [Abstract][Full Text] [Related]
6. Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score.
Westphalen CB; Fine AD; André F; Ganesan S; Heinemann V; Rouleau E; Turnbull C; Garcia Palacios L; Lopez JA; Sokol ES; Mateo J
Clin Cancer Res; 2022 Apr; 28(7):1412-1421. PubMed ID: 34740923
[TBL] [Abstract][Full Text] [Related]
7. Mutational landscape of homologous recombination-related genes in small-cell lung cancer.
Wu S; Zhang Y; Zhang Y; Chen LH; Ouyang HF; Xu X; Du Y; Ti XY
Cancer Med; 2023 Feb; 12(4):4486-4495. PubMed ID: 36053931
[TBL] [Abstract][Full Text] [Related]
8. Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications.
Moretto R; Elliott A; Zhang J; Arai H; Germani MM; Conca V; Xiu J; Stafford P; Oberley M; Abraham J; Spetzler D; Rossini D; Antoniotti C; Marshall J; Shields A; Lopes G; Lonardi S; Pietrantonio F; Tomasello G; Passardi A; Tamburini E; Santini D; Aprile G; Masi G; Falcone A; Lenz HJ; Korn M; Cremolini C
J Natl Cancer Inst; 2022 Feb; 114(2):271-279. PubMed ID: 34469533
[TBL] [Abstract][Full Text] [Related]
9.
Zimmer K; Puccini A; Xiu J; Baca Y; Spizzo G; Lenz HJ; Battaglin F; Goldberg RM; Grothey A; Shields AF; Salem ME; Marshall JL; Korn WM; Wolf D; Kocher F; Seeber A
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32455893
[TBL] [Abstract][Full Text] [Related]
10. Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer.
Sammons S; Elliott A; Barroso-Sousa R; Chumsri S; Tan AR; Sledge GW; Tolaney SM; Torres ETR
Front Oncol; 2023; 13():1235902. PubMed ID: 37637072
[TBL] [Abstract][Full Text] [Related]
11. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
12. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
13. Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.
Park W; Chen J; Chou JF; Varghese AM; Yu KH; Wong W; Capanu M; Balachandran V; McIntyre CA; El Dika I; Khalil DN; Harding JJ; Ghalehsari N; McKinnell Z; Chalasani SB; Makarov V; Selenica P; Pei X; Lecomte N; Kelsen DP; Abou-Alfa GK; Robson ME; Zhang L; Berger MF; Schultz N; Chan TA; Powell SN; Reis-Filho JS; Iacobuzio-Donahue CA; Riaz N; O'Reilly EM
Clin Cancer Res; 2020 Jul; 26(13):3239-3247. PubMed ID: 32444418
[TBL] [Abstract][Full Text] [Related]
14. The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis.
Ibrahim EM; Kazkaz GA; Al-Mansour MM; Al-Foheidi ME
Breast Cancer Res Treat; 2015 Aug; 152(3):463-76. PubMed ID: 26105797
[TBL] [Abstract][Full Text] [Related]
15. Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma.
Nasioudis D; Latif NA; Ko EM; Cory L; Kim SH; Martin L; Simpkins F; Giuntoli R
Gynecol Oncol; 2023 Oct; 177():14-19. PubMed ID: 37611378
[TBL] [Abstract][Full Text] [Related]
16. Investigation of PALB2 Mutation and Correlation With Immunotherapy Biomarker in Chinese Non-Small Cell Lung Cancer Patients.
Zhang J; Tang S; Zhang C; Li M; Zheng Y; Hu X; Huang M; Cheng X
Front Oncol; 2021; 11():742833. PubMed ID: 35087742
[TBL] [Abstract][Full Text] [Related]
17. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
[TBL] [Abstract][Full Text] [Related]
18. Examining the prevalence of homologous recombination repair defects in ER+ breast cancers.
Moore GM; Powell SN; Higginson DS; Khan AJ
Breast Cancer Res Treat; 2022 Apr; 192(3):649-653. PubMed ID: 35092538
[TBL] [Abstract][Full Text] [Related]
19. Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes.
Emelyanova M; Pudova E; Khomich D; Krasnov G; Popova A; Abramov I; Mikhailovich V; Filipenko M; Menshikova S; Tjulandin S; Pokataev I
Ther Adv Med Oncol; 2022; 14():17588359221083050. PubMed ID: 35309086
[TBL] [Abstract][Full Text] [Related]
20. Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.
Yndestad S; Engebrethsen C; Herencia-Ropero A; Nikolaienko O; Vintermyr OK; Lillestøl RK; Minsaas L; Leirvaag B; Iversen GT; Gilje B; Blix ES; Espelid H; Lundgren S; Geisler J; Aase HS; Aas T; Gudlaugsson EG; Llop-Guevara A; Serra V; Janssen EAM; Lønning PE; Knappskog S; Eikesdal HP
JCO Precis Oncol; 2023 Sep; 7():e2300338. PubMed ID: 38039432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
